Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Alastair Smith, Avacta Group CEO gives an Operational Update


Valirx Share Price (VAL)



Share Price Information for Valirx (VAL)


Share Price: 1.90Bid: 1.80Ask: 2.00Change: 0.00 (0.00%)No Movement on Valirx
Spread: 0.20Spread as %: 11.11%Open: 1.90High: 1.90Low: 1.80Yesterday’s Close: 1.90

Valirx Plc Ord 0.1P

Valirx is listed in the FTSE AIM All-Share
Valirx is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
1.90
Share Price SpacerBid
1.80
Share Price SpacerAsk
2.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
1,164,837
Share Price SpacerOpen
1.90
Share Price SpacerHigh
1.90
Share Price SpacerLow
1.80
Share Price SpacerClose
1.90
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 531.63m £10.10m 30,000

52 Week High 7.73 52 Week High Date 12-DEC-2017
52 Week Low 0.90 52 Week Low Date 20-NOV-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
16 168,924 995,913 -1.000 -1.90 0.00 0.00


London South East Users info for Valirx




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

21-Sep-18
16:20:27
1.92
500,000
Buy* 
1.80
2.00
9,600
Trade Type:
Ordinary
Delayed publication

21-Sep-18
16:29:17
1.95
100,000
Buy* 
1.80
2.00
1,950
Trade Type:
Ordinary

21-Sep-18
16:20:37
1.92
150,000
Buy* 
1.80
2.00
2,880
Trade Type:
Ordinary




View more Valirx trades >>

Directors Deals for Valirx (VAL)
Trade DateActionNotifierPriceCurrencyAmountHolding
15-Mar-17Placing
Trade Notifier Information for Valirx
Satu Vainikka held the position of CEO at Valirx at the time of this trade.
 Satu Vainikka
2.5GBX400,0001024909
15-Mar-17Placing
Trade Notifier Information for Valirx
Gerald Desler held the position of CFO at Valirx at the time of this trade.
 Gerald Desler
2.5GBX400,000941875
15-Mar-17Placing
Trade Notifier Information for Valirx
George Morris held the position of Non-Executive Director at Valirx at the time of this trade.
 George Morris
2.5GBX400,000988287
View more Valirx directors dealings >>


tozerk
Posts: 3,033
Opinion:No Opinion
Price:1.90
RE: Video Interview: 6th Sep 2018
Fri 21:39
johandesilva You must not have followed VAL for some time to believe the propaganda published by the BOD.

There is no evidence they will deliver any benefit for shareholders. Trusting their word does not work.
tozerk
Posts: 3,033
Opinion:No Opinion
Price:1.90
RE: Video Interview: 6th Sep 2018
Fri 21:19
Anything not published in an RNS is merely gossip.
If he's confident make it official, publish an RNS with details.
HardToHandle
Posts: 2,071
Opinion:No Opinion
Price:1.90
RE: Video interview DR Morris
Fri 20:00
That's the trouble with Morris IMO , he's not believable !
Wishfulthinker
Posts: 593
Opinion:No Opinion
Price:1.90
Video interview DR Morris
Fri 16:12
Inspite of having given up hope of ever seeing my investment recover, it does sound as is if there is progress on all fronts...plodding... but forwards not backwards. 401 apparently will be first out of the gates with a JV...may be announced soon [Val speak for xx months] and 201 continues to produce good results...they are recruiting for dosing at the higher level...still only being trialled in advanced Ca prostate.....whereas it may eventually be used as a preventative or early disease modifier...after many of us have departed this planet I fear.
desamax
Posts: 1,088
Opinion:No Opinion
Price:1.90
I see YA are at it again
Fri 14:56
This time with Fronterra resources.
View more share chat for Valirx (VAL) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.